In 2003, Scott Rocklage, PhD, joined the team of 5AM Ventures as a Venture Partner. Just a short time later, he became the Managing Partner in 2004. Dr. Scott Rocklage has a lengthy background in having leadership positions. He has more than 30 years in healthcare management. His leadership roles consisted of strategies that lead to an outstanding approval of three U.S. New Drug Applications by the FDA, such as the Omniscan, Teslascan and the Cubicin. Additionally, he enrolled six possible drugs into clinical experiments.
Dr. Rocklage has been the Chairman and Chief Executive Officer of Cubist Pharmaceuticals. He became President and Chief Executive Officer of Nycomed Salutar as well. He successfully held R&D roles at Salutar and Catalytica.
Dr. Scott Rocklage is a present member of a variety of boards. He currently participates as the Board Chairman of Achaogen, Relypsa, Rennovia, Kinestral, Cidara and Semprus. Other boards include WaveRx, Pulmatrix and Variation and the Board of Associates at the Whitehead Institute. Not to mention that he previously served as Executive Chairman of Ilypsa, which was purchased by Amgen and Miikana, which was purchased by EntreMed and read full article.
He is also the former Board Chairman of Novira, which was acquired by J&J.
Dr. Rocklage has an extensive educational background to match his years of experience. He obtained his Bachelors of Science degree in Chemistry from the University of California, Berkeley, and worked hard to gain his PhD in Chemistry from the Massachusetts Institute of Technology (MIT). While attending, he performed research in the laboratory named after Richard R. Schrock and learn more about Scott Rocklage.
More about Scott Rocklage
Dr. Scott Rocklage has invented and co-invented more than 30 U.S. patents. He also has over 100 publications that has been peer-reviewed.
Dr. Scott Rocklage is located in the Boston, MA office.
More visit: http://www.rennovia.com/team/scott-m-rocklage/